| Literature DB >> 26365179 |
Fanny Dupuy1, Sébastien Tabariès2, Sylvia Andrzejewski1, Zhifeng Dong2, Julianna Blagih3, Matthew G Annis2, Atilla Omeroglu4, Dongxia Gao5, Samuel Leung5, Eitan Amir6, Mark Clemons7, Adriana Aguilar-Mahecha8, Mark Basik8, Emma E Vincent3, Julie St-Pierre1, Russell G Jones9, Peter M Siegel10.
Abstract
Metabolic reprogramming is a hallmark of cellular transformation, yet little is known about metabolic changes that accompany tumor metastasis. Here we show that primary breast cancer cells display extensive metabolic heterogeneity and engage distinct metabolic programs depending on their site of metastasis. Liver-metastatic breast cancer cells exhibit a unique metabolic program compared to bone- or lung-metastatic cells, characterized by increased conversion of glucose-derived pyruvate into lactate and a concomitant reduction in mitochondrial metabolism. Liver-metastatic cells displayed increased HIF-1α activity and expression of the HIF-1α target Pyruvate dehydrogenase kinase-1 (PDK1). Silencing HIF-1α reversed the glycolytic phenotype of liver-metastatic cells, while PDK1 was specifically required for metabolic adaptation to nutrient limitation and hypoxia. Finally, we demonstrate that PDK1 is required for efficient liver metastasis, and its expression is elevated in liver metastases from breast cancer patients. Our data implicate PDK1 as a key regulator of metabolism and metastatic potential in breast cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26365179 DOI: 10.1016/j.cmet.2015.08.007
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287